{"id":265,"date":"2021-07-13T10:00:00","date_gmt":"2021-07-13T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=265"},"modified":"2025-09-10T06:27:48","modified_gmt":"2025-09-10T06:27:48","slug":"china-bd-2021-allist-pharma-and-arrivent-enters-a-150-million-usd-license-on-egfr-tki-orelabrutinib-for-the-potential-treatment-of-multiple-sclerosis-ms","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2021\/265.html","title":{"rendered":"[China BD 2021] Allist Pharma and ArriVent enters a 150 million USD License on EGFR TKI Orelabrutinib for the potential treatment of multiple sclerosis (MS)"},"content":{"rendered":"\n<p>Announced Date: 2021-07-12 (July 12, 2021)<\/p>\n\n\n\n<p>Asset Name: Orelabrutinib<\/p>\n\n\n\n<p>Licensor (Seller): InnoCare Pharma (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Biogen<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: Bruton\u2019s tyrosine kinase inhibitor (BTKi)<\/p>\n\n\n\n<p>Potential Indication: oncology, autoimmune diseases <\/p>\n\n\n\n<p>Current Stage: Phase 2 trial<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Biogen will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), <\/p>\n\n\n\n<p>while InnoCare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan).\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>InnoCare will receive<\/p>\n\n\n\n<p>Upfront payment of\u00a0$125 million,<\/p>\n\n\n\n<p>Development, commercial milestone payments up to $ 812.5 million.<\/p>\n\n\n\n<p>Tiered royalties in the low to high teens on potential future net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-innocare-announce-license-and-collaboration-agreement\">Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis | Biogen<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of \u201cInnoCare Pharma\u201c\uff0c\u8bfa\u8bda\u5065\u534e<\/p>\n\n\n\n<p>Chinese Name of \u201cOrelabrutinib\u201c \uff0c\u5965\u5e03\u66ff\u5c3c<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2021-07-12 (July 12, 2021) Asset Name: Orelabrutinib Licensor (Seller): InnoCare Pharma (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2021] Allist Pharma and ArriVent enters a 150 million USD License on EGFR TKI Orelabrutinib for the potential treatment of multiple sclerosis (MS)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2021\/265.html\"><span class=\"screen-reader-text\">[China BD 2021] Allist Pharma and ArriVent enters a 150 million USD License on EGFR TKI Orelabrutinib for the potential treatment of multiple sclerosis (MS)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-265","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=265"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/265\/revisions"}],"predecessor-version":[{"id":266,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/265\/revisions\/266"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}